Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study-Reference-Cited by-同舟云学术

Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study

Published:2015-04 Issue:4 Volume:16 Page:406-416
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Kawai Akira,Araki Nobuhito,Sugiura Hideshi,Ueda Takafumi,Yonemoto Tsukasa,Takahashi Mitsuru,Morioka Hideo,Hiraga Hiroaki,Hiruma Toru,Kunisada Toshiyuki,Matsumine Akihiko,Tanase Takanori,Hasegawa Tadashi,Takahashi Shunji

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. Soft-tissue sarcomas in adults;Clark;N Engl J Med,2005

2. Translocation-related sarcomas;Mertens;Semin Oncol,2009

3. NCCN. Clinical practice guidelines in oncology. Soft tissue sarcoma, version 2. 2014.

4. Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Ann Oncol,2014

Cited by 188 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world efficacy, safety data and predictive clinical parameters for treatment outcomes in advanced soft tissue sarcoma treated with combined immunotherapy and antiangiogenic therapy;BMC Cancer;2024-08-20

2. Long-term efficacy of eribulin in patients with advanced myxoid liposarcoma resistant to trabectedin: A case report;JOS Case Reports;2024-06

3. DNA-Binding Agent Trabectedin Combined With Recombinant Methioninase Is Synergistic to Decrease Fibrosarcoma Cell Viability and Induce Nuclear Fragmentation But Not Synergistic on Normal Fibroblasts;Anticancer Research;2024-05-31

4. UK guidelines for the management of soft tissue sarcomas;British Journal of Cancer;2024-05-11

5. Predicting Trabectedin Efficacy in Soft Tissue Sarcoma: Inflammatory Biomarker Analysis;Anticancer Research;2024-04-27